Christopher L. Cioffi

2.4k citations

53 papers · 1.6k indexed · 3 hit papers · h-index 20

Co-authors: Andrew Blauvelt Luke Peterson Kristian Reich Veerle Vanvoorden Cynthia Madden Kim Papp Richard B. Warren Richard G. Langley
Topics: Psoriasis: Treatment and Pathogenesis (20 papers)Autoimmune Bullous Skin Diseases (9 papers)Retinoids in leukemia and cellular processes (7 papers)
Cited by: Dermatology Immunology Rheumatology
Journals: New England Journal of Medicine The Lancet Journal of Biological Chemistry
Partner nations: United States United Kingdom Belgium

In The Last Decade

Christopher L. Cioffi

51 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bimekizumab versus Secukinumab in Plaque Psoriasis

2021 230 citations Kristian Reich, Richard B. Warren et al. profile →
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

2021 170 citations Kenneth B. Gordon, Kristian Reich et al. The Lancet profile →
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

2021 169 citations Kristian Reich, Kim Papp et al. The Lancet profile →

Peers

Countries citing papers authored by Christopher L. Cioffi

Since Specialization

Citations

This map shows the geographic impact of Christopher L. Cioffi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher L. Cioffi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher L. Cioffi more than expected).

Fields of papers citing papers by Christopher L. Cioffi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher L. Cioffi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher L. Cioffi. The network helps show where Christopher L. Cioffi may publish in the future.

Co-authorship network of co-authors of Christopher L. Cioffi

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher L. Cioffi. A scholar is included among the top collaborators of Christopher L. Cioffi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher L. Cioffi. Christopher L. Cioffi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hybrid Pd0.1Cu0.9Co2O4 nano-flakes: a novel, efficient and reusable catalyst for the one-pot heck and Suzuki couplings with simultaneous transesterification reactions under microwave irradiation 2024 ·Frontiers in Chemistry ·Ashok R. Patel,G. Maity,(unknown),Laksmikanta Adak,Christopher L. Cioffi,Subhash Banerjee	1
2	The efficacy of the analgesic GlyT2 inhibitor, ORG25543 , is determined by two connected allosteric sites 2023 ·Journal of Neurochemistry ·(unknown),(unknown),Katie A. Wilson,(unknown),Patrick Sutton,S. Jayakumar,Christopher L. Cioffi,Megan L. O’Mara,Robert J. Vandenberg	5
3	The novel visual cycle inhibitor (±)-RPE65-61 protects retinal photoreceptors from light-induced degeneration 2022 ·PLoS ONE ·Yuhong Wang,Xiang Ma,(unknown),Arun Raja,(unknown),Konstantin Petrukhin,Christopher L. Cioffi,Jian‐xing Ma,Gennadiy Moiseyev	6
4	Structural similarities between SARS-CoV2 3CLpro and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals 2022 ·Frontiers in Chemistry ·Khushboo Bafna,Christopher L. Cioffi,Robert M. Krug,G.T. Montelione	9
5	Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials 2021 ·Dermatology and Therapy ·Richard B. Warren,Alice B. Gottlieb,Joseph F. Merola,(unknown),Christopher L. Cioffi,Luke Peterson,(unknown),(unknown)	9
6	27380 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial 2021 ·Journal of the American Academy of Dermatology ·Andrew Blauvelt,Jashin J. Wu,Kristian Reich,Melinda Gooderham,Mark Lebwohl,Katy White,Nancy Cross,Christopher L. Cioffi,Kim Papp	6
7	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialbreakdown → 2021 ·The Lancet ·Kristian Reich,Kim Papp,Andrew Blauvelt,Richard G. Langley,April W. Armstrong,Richard B. Warren,Kenneth B. Gordon,Joseph F. Merola,Yukari Okubo,Cynthia Madden,Maggie Haitian Wang,Christopher L. Cioffi,Veerle Vanvoorden,Mark Lebwohl	169
8	Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study 2020 ·Journal of the American Academy of Dermatology ·Andrew Blauvelt,Kim Papp,Joseph F. Merola,Alice B. Gottlieb,Nancy Cross,Cynthia Madden,Maggie Haitian Wang,Christopher L. Cioffi,C.E.M. Griffiths	50
9	14020 Durability of responses with bimekizumab, a selective dual inhibitor of interleukin-17A and -17F, in moderate to severe chronic plaque psoriasis in a 60-week randomized, double-blinded, phase 2b study (BE ABLE 2) 2020 ·Journal of the American Academy of Dermatology ·Andrew Blauvelt,Joseph F. Merola,Kim Papp,Melinda Gooderham,Alice B. Gottlieb,Christopher L. Cioffi,Luke Peterson,Nancy Cross,C.E.M. Griffiths,Diamant Thaçi	2
10	Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis 2020 ·Dermatology and Therapy ·Alice B. Gottlieb,(unknown),Christopher L. Cioffi,Luke Peterson,Richard B. Warren	6
11	Stringent response governs the oxidative stress resistance and virulence of Francisella tularensis 2019 ·PLoS ONE ·Zhuo Ma,Kayla C. King,(unknown),(unknown),(unknown),Christopher L. Cioffi,Chandra Shekhar Bakshi,Meenakshi Malik	19
12	A novel RPE65 inhibitor CU239 suppresses visual cycle and prevents retinal degeneration 2018 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·(unknown),Gennadiy Moiseyev,Konstantin Petrukhin,Christopher L. Cioffi,(unknown),Yusuke Takahashi,Jian‐xing Ma	16
13	Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial 2018 ·Journal of the American Academy of Dermatology ·Kim Papp,Joseph F. Merola,Alice B. Gottlieb,C.E.M. Griffiths,Nancy Cross,Luke Peterson,Christopher L. Cioffi,Andrew Blauvelt	157
14	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study 2016 ·The Lancet ·(unknown),Gerd‐Rüdiger Burmester,Bernard Combe,Jeffrey R. Curtis,Stephen Hall,Boulos Haraoui,Ronald van Vollenhoven,Christopher L. Cioffi,(unknown),Leon Gervitz,Lucian Ionescu,Luke Peterson,Roy Fleischmann	134
15	Inhibitors of Glycine Transporter-1: Potential Therapeutics for the Treatment of CNS Disorders 2016 ·Current Topics in Medicinal Chemistry ·Christopher L. Cioffi,Peter R. Guzzo	22
16	Design, Synthesis, and Evaluation of Nonretinoid Retinol Binding Protein 4 Antagonists for the Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease 2014 ·Journal of Medicinal Chemistry ·Christopher L. Cioffi,(unknown),Emily Freeman,(unknown),Ping Chen,Douglas G. Stafford,(unknown),(unknown),Lei Zhu,Douglas B. Kitchen,Keith D. Barnes,Bóglárka Rácz,Qiong Qin,Enrique L. Michelotti,Charles L. Cywin,William H. Martin,Paul G. Pearson,Graham Johnson,Konstantin Petrukhin	42
17	Modulation of NMDA receptor function as a treatment for schizophrenia 2013 ·Bioorganic & Medicinal Chemistry Letters ·Christopher L. Cioffi	23
18	Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome 2010 ·Bioorganic & Medicinal Chemistry Letters ·David D. Manning,Christopher L. Cioffi,Alexander Usyatinsky,(unknown),(unknown),(unknown),Zhenjun Zhang,(unknown),(unknown),(unknown),(unknown),(unknown),Svetlana V. Dobritsa,(unknown),William G. Earley,(unknown),Catherine Brady,Nicholas M. Barnes,Marlene L. Cohen,Peter R. Guzzo	9
19	8-Aminocyclazocine analogues: synthesis and structure–activity relationships 2000 ·Bioorganic & Medicinal Chemistry Letters ·Mark P. Wentland,(unknown),Christopher L. Cioffi,Yingchun Ye,Wenhu Duan,Dana J. Cohen,(unknown),Jean M. Bidlack	23
20	Synthesis of 24.xi.-Squalamine, an Anti-Infective Steroidal Polyamine 1995 ·The Journal of Organic Chemistry ·(unknown),(unknown),Christopher L. Cioffi,Sean Trapp,(unknown),(unknown),William A. Kinney,Leah L. Frye	42

About Christopher L. Cioffi

Christopher L. Cioffi is a scholar working on Immunology, Dermatology and Ophthalmology, having authored 53 papers that have together received 1.6k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (20 papers), Autoimmune Bullous Skin Diseases (9 papers) and Retinoids in leukemia and cellular processes (7 papers). The work is most often cited by research in Dermatology (480 citations), Immunology (909 citations) and Rheumatology (349 citations). Christopher L. Cioffi has collaborated with scholars based in United States, United Kingdom and Belgium. Frequent co-authors include Andrew Blauvelt, Luke Peterson, Kristian Reich, Veerle Vanvoorden, Cynthia Madden, Kim Papp, Richard B. Warren, Richard G. Langley, Joseph F. Merola and Nancy Cross. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact